The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia

Familial Cancer

Volumn 12, Issue 4, 2013, Pages 587-595

  Teo, Zhi L ^a   Sawyer, Sarah D ^b   James, Paul A ^a,b   Mitchell, Gillian ^a,b   Trainer, Alison H ^b,c   Lindeman, Geoffrey J ^a,c,d   Shackleton, Kylie ^c   Cicciarelli, Linda ^b   Southey, Melissa C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

BRCA1 and BRCA2 mutation negative; Familial cancer centre; Hereditary breast cancer; PALB2

Indexed keywords

DNA; PALB2 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; AUSTRALIA; BREAST CANCER; CANCER CENTER; CANCER DIAGNOSIS; CANCER INCIDENCE; CLINICAL EVALUATION; DNA SCREENING; FAMILIAL CANCER; FAMILY HISTORY; GENE IDENTIFICATION; GENE MUTATION; HIGH RISK POPULATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; BREAST NEOPLASMS; CANCER CARE FACILITIES; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INCIDENCE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84888197794     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-013-9620-4     Document Type: Article

References (29)

1. Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321-345. doi: 10.1146/annurev.genom.9.081307.164339
2. Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MRE, Venter DJ, Hopper JL (2003) Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 95(6):448-457
3. Lynch HT, Watson P, Conway T, Fitzsimmons ML, Lynch J (1988) Breast-cancer family history as a risk factor for early onset breast-cancer. Breast Cancer Res Treat 11(3):263-267
4. Houlston RS, McCarter E, Parbhoo S, Scurr JH, Slack J (1992) Family history and risk of breast-cancer. J Med Genet 29(3):154-157
5. Colditz GA, Rosner BA, Speizer FE (1996) Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 88(6):365-371
6. Frank TS, Deffenbaugh AM, Hulick M, Gumpper K (1999) Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2. Dis Markers 15(1-3):89-92
7. Negri E, Braga C, LaVecchia C, Franceschi S, Parazzini F (1997) Family history of cancer and risk of breast cancer. Int J Cancer 72(5):735-738
8. Poole CA, Byers T, Calle EE, Bondy J, Fain P, Rodriguez C (1999) Influence of a family history of cancer within and across multiple sites on patterns of cancer mortality risk for women. Am J Epidemiol 149(5):454-462
9. Beral V, Bull D, Doll R, Peto R, Reeves G (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389-1399
10. Hemminki K, Granstrom C (2003) Familial breast cancer: scope for more susceptibility genes? Breast Cancer Res Treat 82(1):17-22. doi: 10.1023/B:BREA.0000003871.38587.8b
11. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91(11):943-949. doi: 10.1093/jnci/91.11.943
12. Cui JS, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, Giles GG, McCredie MRE, Hopper JL (2001) After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am J Hum Genet 68(2):420-431
13. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38(8):873-875
14. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton DF, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber BL, Rahman N, Stratton MR (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31(1):55-59. doi: 10.1038/ng879
15. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11):1239-1241. doi: 10.1038/ng1902
16. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165-167
17. Sy SMH, Huen MSY, Chen JJ (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 106(17):7155-7160. doi: 10.1073/pnas.0811159106
18. Zhang F, Ma JL, Wu JX, Ye L, Cai H, Xia B, Yu XC (2009) PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response. Curr Biol 19(6):524-529. doi: 10.1016/j.cub.2009.02.018
19. Byrnes GB, Southey MC, Hopper JL (2008) Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res 10(3):208
20. Southey M, Teo Z, Dowty J, Odefrey F, Park D, Tischkowitz M, Sabbaghian N, Apicella C, Byrnes G, Winship I, Baglietto L, Giles G, Goldgar D, Foulkes W, Hopper J, kConFab, the Breast Cancer Family R (2010) A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res 12(6):R109
21. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117-1130
22. Sawyer S, Mitchell G, McKinley J, Chenevix-Trench G, Beesley J, Chen XQ, Bowtell D, Trainer AH, Harris M, Lindeman GJ, James PA (2012) A role for common genomic variants in the assessment of familial breast cancer. J Clin Oncol
23. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701-2712
24. NBOCC (2012) Advice about familial aspects of breast cancer and epithelial ovarian cancer: a guide for health professionals. http://canceraustralia.nbocc.org.au/
25. Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallee MP, Tavtigian SV, Concannon P, Foulkes WD, Bernstein L, Bernstein JL, Begg CB (2012) Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat 33(4):674-680. doi: 10.1002/humu.22022
26. Elston CW, Ellis IO, Pinder SE (1999) Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 31(3):209-223. doi: 10.1016/s1040-8428(99) 00034-7
27. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, Bowden NA, Scott RJ (2011) BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat 127(3):853-859. doi: 10.1007/s10549-011-1443-0
28. Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC (2011) Contribution of inherited mutations in the BRCA2-Interacting protein PALB2 to familial breast cancer. Cancer Res 71(6):2222-2229. doi: 10.1158/0008-5472.can-10-3958
29. Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips KA, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G (2006) Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8 (1):R12. doi: 10.1186/bcr1377